Genelabs Announces Board Approval of Reverse Stock Split (Hep C Treatment)

Genelabs Announces Board Approval of Reverse Stock Split
FinanzNachrichten - Dec 06 3:45 PM
REDWOOD CITY, Calif., Dec. 6 /PRNewswire-FirstCall/ -- Genelabs Technologies, ( Nachrichten ) Inc. announced today that its board of directors has approved the implementation of a one-for-five reverse split of the company's common stock.Save to My Web

Affymetrix and Vita Genomics Collaborate to Develop Microarray-Based IVD Products
RedNova - Dec 26 4:17 PM
Affymetrix Inc.Save to My Web

InterMune Completes Divestiture of Infergen(R) for up to $135.5 Million in Cash
FinanzNachrichten - Jan 03 5:47 AM
BRISBANE, Calif., Jan. 3 /PRNewswire-FirstCall/ -- InterMune, ( Nachrichten ) Inc. announced today the completion of the sale of its United States and Canadian rights to Infergen(R) (interferon alfacon-1), approved for the treatment of chronic hepatitis C virus (HCV) infections, to Valeant Pharmaceuticals International .Save to My Web

West Side weekly calendar
El Paso Times - Dec 23 2:15 AM
All calendar items are in El Paso unless otherwise stated. While it is unlikely groups and organizations will meet on Christmas, they are listed here to reflect regular meeting place and time for those interested.Save to My Web

Novel Drugs From Idenix/Novartis, Vertex, Schering-Plough, and Gilead/Achillion Have Potential to Revolutionize the
[Press Release] PR Newswire via Yahoo! Finance - Dec 12 5:00 AM
Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that the launch of novel polymerase and protease inhibitors have the potential to revolutionize the treatment of the hepatitis C virus .Save to My Web

Tatas to set up HCV plant in W Bengal
The Economic Times - Dec 29 5:54 AM
Leading automobile manufacturer Tata Motors Limited has shortlisted West Bengal as the possible location for setting up a greenfield truck manufacturing unit.Save to My Web